| scholarly article | Q13442814 |
| P50 | author | Dennis Deapen | Q87033719 |
| Jennifer L. Lund | Q89058482 | ||
| Angela Mariotto | Q90467520 | ||
| Kathleen A. Cronin | Q125588542 | ||
| Joan L. Warren | Q125599790 | ||
| P2093 | author name string | Anne-Michelle Noone | |
| Timothy McNeel | |||
| P2860 | cites work | External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews | Q36936083 |
| Potential for cancer related health services research using a linked Medicare-tumor registry database. | Q50125205 | ||
| Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999 | Q79220367 | ||
| Utilization and expense of adjuvant cancer therapies following radical prostatectomy | Q83509987 | ||
| Identifying specific chemotherapeutic agents in Medicare data: a validation study | Q30413422 | ||
| Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. | Q30538788 | ||
| Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology and End Results | Q30578076 | ||
| Validity of cancer registry data for measuring the quality of breast cancer care | Q30696279 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Utility of the SEER-Medicare data to identify chemotherapy use. | Q30714828 | ||
| Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment | Q33180113 | ||
| Studying radiation therapy using SEER-Medicare-linked data | Q33184144 | ||
| Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research | Q33489414 | ||
| Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data | Q33946846 | ||
| Tradeoffs between accuracy measures for electronic health care data algorithms | Q34111706 | ||
| Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure | Q34159971 | ||
| Validation of electronic data on chemotherapy and hormone therapy use in HMOs | Q34244526 | ||
| Reduction in physician reimbursement and use of hormone therapy in prostate cancer | Q34406403 | ||
| Construct validity of medicare chemotherapy claims: the case of 5FU. | Q34553407 | ||
| Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma | Q36059488 | ||
| Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants | Q36200748 | ||
| Cancer surveillance and information: balancing public health with privacy and confidentiality concerns (United States). | Q36457918 | ||
| P433 | issue | 9 | |
| P921 | main subject | Medicare | Q559392 |
| P304 | page(s) | e55-64 | |
| P577 | publication date | 2014-03-15 | |
| P1433 | published in | Medical Care | Q15762119 |
| P1476 | title | Comparison of SEER Treatment Data With Medicare Claims | |
| P478 | volume | 54 |
| Q61807140 | 21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery |
| Q92552251 | A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals |
| Q98468350 | A competing risk analysis of death patterns in male genitourinary cancer |
| Q40061559 | A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma |
| Q90751701 | Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30 |
| Q88644477 | Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes |
| Q52581323 | Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. |
| Q55456781 | Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. |
| Q49873738 | An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States |
| Q64903997 | Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. |
| Q52641223 | Breast cancer survival, survival disparities, and guideline-based treatment. |
| Q50869231 | Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. |
| Q33915023 | Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study |
| Q38808749 | Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. |
| Q96020059 | Comparing national practice versus standard guidelines for the use of adjuvant treatment following robotic surgery for oropharyngeal squamous cell carcinoma |
| Q92683627 | Conditional survival analysis of four treatment strategies for patients with stage I non-small cell lung cancer |
| Q59812853 | Construction of a nomogram predicting the overall survival of patients with distantly metastatic non-small-cell lung cancer |
| Q91336417 | Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends |
| Q37382627 | Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. |
| Q37066097 | Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database |
| Q93134986 | De-escalating chemotherapy for stage II colon cancer? |
| Q88782225 | Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: Estimations based on SEER-Medicare-linked data resource |
| Q93171466 | Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer |
| Q40406236 | Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer? |
| Q55104185 | Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. |
| Q92390779 | Early-onset pancreatic cancer: a population-based study using the SEER registry |
| Q91674970 | Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer |
| Q92532687 | Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial |
| Q93199764 | Factors Associated with Worse Outcome in Early Stage Gastric Cancer Using the Surveillance, Epidemiology, and End Results (SEER) Database |
| Q47443109 | Fertility preservation and survival among young women with early ovarian cancer living in US counties with gynecologic oncologist services |
| Q99412495 | Genomic expression assay testing among American Indian and Alaska Native women with breast cancer |
| Q92804786 | Glioma incidence and survival variations by county-level socioeconomic measures |
| Q89967093 | Hepatic Resection Is Associated With Improved Long-Term Survival Compared to Radio-Frequency Ablation in Patients With Multifocal Hepatocellular Carcinoma |
| Q52717618 | High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. |
| Q35713044 | History of Recreational Physical Activity and Survival After Breast Cancer: The California Breast Cancer Survivorship Consortium |
| Q92631635 | Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases |
| Q36619445 | Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study |
| Q48060567 | Impact of colorectal cancer diagnosis and treatment on health-related quality of life among older Americans: a population-based, case-control study. |
| Q64251306 | Impact of old age on resectable colorectal cancer outcomes |
| Q88732241 | Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma |
| Q89828555 | Incidence of Death From Unintentional Injury Among Patients With Cancer in the United States |
| Q58732194 | Incidence of adrenal gland tumor as a second primary malignancy: SEER-based study |
| Q89560738 | Individual-patient prediction of meningioma malignancy and survival using the Surveillance, Epidemiology, and End Results database |
| Q45074407 | Intended vs. Inferred Treatment after 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. |
| Q36655965 | Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all |
| Q90873378 | Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011 |
| Q88188517 | Molecular Characterization and Mortality From Breast Cancer in Men |
| Q49719060 | Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials |
| Q39901144 | Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis |
| Q40699470 | Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes. |
| Q55025978 | Omission of Postoperative Radiotherapy in Women Aged 65 Years or Older With Tubular Carcinoma of the Breast After Breast-Conserving Surgery. |
| Q90471688 | Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia |
| Q64245368 | Opportunities for use of radiation therapy in penile cancer based on patterns of care in the United States from 2007 to 2013 |
| Q64114245 | Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma |
| Q36915217 | Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. |
| Q90282562 | Population-Based Analysis of Demographic and Socioeconomic Disparities in Pediatric CNS Cancer Survival in the United States |
| Q91949849 | Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases |
| Q53828122 | Post-treatment surveillance testing of patients with colorectal cancer and the association with survival: protocol for a retrospective cohort study of the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. |
| Q49540661 | Primary Urinary Tract Lymphoma: Rare but Aggressive |
| Q90445402 | Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival |
| Q39067407 | Primary intramedullary spinal cord lymphoma: a population-based study |
| Q48102221 | Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. |
| Q46508410 | Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. |
| Q36807598 | Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis |
| Q89966742 | Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study |
| Q40108206 | Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers |
| Q92859973 | Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014 |
| Q94571977 | Real-world impact of postmastectomy radiotherapy in T1-2 breast cancer with one to three positive lymph nodes |
| Q40344810 | Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma |
| Q64121884 | Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study |
| Q90736428 | Risk of Alzheimer's Disease in Cancer Patients: Analysis of Mortality Data from the US SEER Population-Based Registries |
| Q93054422 | Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer |
| Q47097386 | Sites of metastasis and overall survival in esophageal cancer: a population-based study |
| Q88356461 | Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors |
| Q95822336 | Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors |
| Q50089775 | Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study |
| Q93152931 | Survival Differences Between Males and Females Diagnosed With Childhood Cancer |
| Q88585381 | Survival analysis of patients with spinal chordomas |
| Q93101350 | Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment |
| Q49350138 | The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer |
| Q60951040 | The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes |
| Q55173078 | The Effect of Marital Status on Nasopharyngeal Carcinoma Survival: A Surveillance, Epidemiology and End Results Study. |
| Q93048401 | The Effect of Post-mastectomy Radiotherapy in Patients With Metaplastic Breast Cancer: An Analysis of SEER Database |
| Q55005151 | The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. |
| Q100428095 | The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data |
| Q60928582 | The effect of marital status on glioma patient survival: analysis of 617 cases: A SEER-based study |
| Q59329849 | The effects of postoperative radiotherapy on survival outcomes in patients under 65 with estrogen receptor positive tubular breast carcinoma |
| Q91756516 | The prevalence, associated factors for bone metastases development and prognosis in newly diagnosed ovarian cancer: a large population based real-world study |
| Q55436255 | The prognosis and effects of local treatment strategies for orbital embryonal rhabdomyosarcoma: a population-based study. |
| Q36009600 | The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma |
| Q90611288 | The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity |
| Q48185729 | Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. |
| Q55447130 | Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. |
| Q38857898 | Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study |
| Q104288843 | Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer |
| Q36913542 | Underutilization of gene expression profiling for early-stage breast cancer in California |
| Q92413756 | Unlocking the potential of population-based cancer registries |
| Q47288856 | Using Medical Claims Analyses to Understand Interventions for Parkinson Patients |
| Q57106633 | Using hospital medical record data to assess the accuracy of the SEER Los Angeles Cancer Surveillance Program for initial treatment of prostate cancer: a small pilot study |
Search more.